CNS specialist Lundbeck (LUND: CO) has become the latest pharma company to announce a collaboration with IBM Watson Health.
The partnership will give the Danish company access to the Watson supercomputer’s technology and extensive data sets, providing new opportunities to develop medicines to treat psychiatric and neurological disorders such as schizophrenia and Parkinson's disease.
"IBM can help create data-driven hypotheses based on Lundbeck's questions, which can be used in research on fighting psychiatric and neurological disorders"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze